Dimensional Fund Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Dimensional Fund Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$249K	Buy	67,982 +46,304	+214%	+$154K	﹤0.01%	3049
2026 Q1	$66.6K	Sell	21,678 -8,382	-28%	-$32.4K	﹤0.01%	3154
2025 Q4	$123K	Buy	+30,060	New	+$149K	﹤0.01%	3131
2025 Q3	–	Sell	-34,053	Closed	-$172K	–	3334
2025 Q2	$172K	Sell	34,053 -1,682,722	-98%	-$8.27M	﹤0.01%	3134
2025 Q1	$9.09M	Buy	1,716,775 +8,735	+0.5%	+$63.7K	﹤0.01%	2290
2024 Q4	$11.5M	Sell	1,708,040 -9,739	-0.6%	-$65.5K	﹤0.01%	2250
2024 Q3	$11.3M	Sell	1,717,779 -202,398	-11%	-$1.45M	﹤0.01%	2249
2024 Q2	$14.4M	Sell	1,920,177 -174,823	-8%	-$1.52M	﹤0.01%	2109
2024 Q1	$20.9M	Sell	2,095,000 -42,110	-2%	-$469K	0.01%	1959
2023 Q4	$21.1M	Buy	2,137,110 +1,291,946	+153%	+$9.21M	0.01%	1959
2023 Q3	$6.47M	Buy	845,164 +60,376	+8%	+$602K	﹤0.01%	2443
2023 Q2	$5.86M	Buy	784,788 +87,503	+13%	+$612K	﹤0.01%	2468
2023 Q1	$4.65M	Buy	+697,285	New	+$5.53M	﹤0.01%	2504

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Dimensional Fund Advisors's RXRX Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 214% in Q2 2026, buying an estimated $154K and bringing the position to 67,982 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #3049.

Dimensional Fund Advisors first reported a position in RXRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $21.1M in Q4 2023. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Dimensional Fund Advisors held 67,982 shares of Recursion Pharmaceuticals worth $249K as of Q2 2026.
Dimensional Fund Advisors bought 46,304 Recursion Pharmaceuticals shares in Q2 2026, an estimated $154K.
Recursion Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #3049 holding.
Dimensional Fund Advisors first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Dimensional Fund Advisors's Recursion Pharmaceuticals position peaked at $21.1M in Q4 2023.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.